Literature DB >> 25637636

A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue.

Janet A Gilbertson1, Jason D Theis2, Julie A Vrana2, Helen Lachmann1, Ashutosh Wechalekar1, Carol Whelan1, Philip N Hawkins1, Ahmet Dogan2, Julian D Gillmore1.   

Abstract

Amyloidosis is caused by deposition in tissues of abnormal protein in a characteristic fibrillar form. There are many types of amyloidosis, classified according to the soluble protein precursor from which the amyloid fibrils are derived. Accurate identification of amyloid type is critical in every case since therapy for systemic amyloidosis is type specific. In ∼20-25% cases, however, immunohistochemistry (IHC) fails to prove the amyloid type and further tests are required. Laser microdissection and mass spectrometry (LDMS) is a powerful tool for identifying proteins from formalin-fixed paraffin-embedded tissues. We undertook a blinded comparison of IHC, performed at the UK National Amyloidosis Centre, and LDMS, performed at the Mayo Clinic, in 142 consecutive biopsy specimens from 38 different tissue types. There was 100% concordance between positive IHC and LDMS, and the latter increased diagnostic accuracy from 76% to 94%. LDMS in expert hands is a valuable tool for amyloid diagnosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  AMYLOID; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY

Mesh:

Substances:

Year:  2015        PMID: 25637636     DOI: 10.1136/jclinpath-2014-202722

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Factoring in the missing link.

Authors:  Nilay Sethi; Reza Sedighi Manesh; Adam Sperling; Scott C Bresler; Nathan T Connell; Lawrence M Tierney
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

2.  Challenges in Experimental Methods.

Authors:  Marlena E Gąsior-Głogowska; Natalia Szulc; Monika Szefczyk
Journal:  Methods Mol Biol       Date:  2022

3.  Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing.

Authors:  William S Phipps; Kelly D Smith; Han-Yin Yang; Clark M Henderson; Hannah Pflaum; Melissa L Lerch; William E Fondrie; Michelle A Emrick; Christine C Wu; Michael J MacCoss; William S Noble; Andrew N Hoofnagle
Journal:  Am J Clin Pathol       Date:  2022-05-04       Impact factor: 5.400

4.  The Clinical Impact of Proteomics in Amyloid Typing.

Authors:  Michelle M Hill; Surendra Dasari; Peter Mollee; Giampaolo Merlini; Catherine E Costello; Bouke P C Hazenberg; Martha Grogan; Angela Dispenzieri; Morie A Gertz; Taxiarchis Kourelis; Ellen D McPhail
Journal:  Mayo Clin Proc       Date:  2021-04-09       Impact factor: 11.104

5.  Personalized Proteomics: The Future of Precision Medicine.

Authors:  Trevor T Duarte; Charles T Spencer
Journal:  Proteomes       Date:  2016-10-01

6.  Mass spectrometry-based absolute quantification of amyloid proteins in pathology tissue specimens: Merits and limitations.

Authors:  Makiko Ogawa; Yukako Shintani-Domoto; Yoshiki Nagashima; Koji L Ode; Aya Sato; Yoshihiro Shimizu; Kenichi Ohashi; Michael H A Roehrl; Tetsuo Ushiku; Hiroki R Ueda; Masashi Fukayama
Journal:  PLoS One       Date:  2020-07-01       Impact factor: 3.240

Review 7.  Advances in the treatment of hereditary transthyretin amyloidosis: A review.

Authors:  Morie A Gertz; Michelle L Mauermann; Martha Grogan; Teresa Coelho
Journal:  Brain Behav       Date:  2019-08-01       Impact factor: 2.708

8.  Proteomic analysis shows that the main constituent of subepidermal localised cutaneous amyloidosis is not galectin-7.

Authors:  Jessica R Chapman; Anna Liu; San S Yi; Enmily Hernandez; Maria Stella Ritorto; Achim A Jungbluth; Melissa Pulitzer; Ahmet Dogan
Journal:  Amyloid       Date:  2020-09-01       Impact factor: 7.141

Review 9.  Proteomics and mass spectrometry in the diagnosis of renal amyloidosis.

Authors:  Maria M Picken
Journal:  Clin Kidney J       Date:  2015-09-11

10.  Systemic amyloidoses and proteomics: The state of the art.

Authors:  Francesca Lavatelli; Andrea di Fonzo; Giovanni Palladini; Giampaolo Merlini
Journal:  EuPA Open Proteom       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.